varenicline (CP-526,555)
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Smoking Cessation
Conditions
Smoking Cessation
Trial Timeline
Jan 1, 2005 → Jun 1, 2006
NCT ID
NCT00143325About varenicline (CP-526,555)
varenicline (CP-526,555) is a phase 3 stage product being developed by Pfizer for Smoking Cessation. The current trial status is completed. This product is registered under clinical trial identifier NCT00143325. Target conditions include Smoking Cessation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00143325 | Phase 3 | Completed |
| NCT00143299 | Phase 3 | Completed |
| NCT00143364 | Phase 3 | Completed |
| NCT00141206 | Phase 3 | Completed |
| NCT00143286 | Phase 3 | Completed |
Competing Products
20 competing products in Smoking Cessation